Use of and Association Between Heart Failure Pharmacological Treatments and Outcomes in Obese Versus Non-Obese Patients with Heart Failure with Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry

Abstract

Obese patients were more likely to receive optimal treatments after adjustment for factors affecting tolerability, suggesting that perceived beyond actual tolerance issues limit GDMT implementation. RASi/ARNi and beta-blockers were associated with lower mortality regardless of obesity, with a greater association between RASi/ARNi and lower cardiovascular death in obese versus non-obese patients when considering competing risk.